PriceSensitive

Nuheara (ASX:NUH) receives US FDA approval, launches HP Hearing PRO

ASX News, Health Care
ASX:NUH      MCAP $21.75M
31 October 2022 13:05 (AEST)

This browser does not support the video element.

Nuheara (NUH) has received clearance from the US Food and Drug Administration (FDA) for its self-fitting over-the-counter (OTC) hearing aid, HP Hearing Pro.

The company’s HP Hearing PRO has been cleared by the FDA under a new product classification code “QUH”.

Following landmark law establishing a regulatory category for OTC hearing aids in the US, the company plans to bring to market its first medical device as the HP Hearing PRO under its worldwide trademark licence agreement for use of HP trademarks on its hearing aids, personal sound amplification devices and accessories.

Retailers and ecommerce partners have placed their initial orders throughout the US, charging the hearing aids at a recommended retail price of US$699 (A$1045) which includes a charge case for on-the-go charging.

Commenting on Nuheara FDA clearance and the hearing aids launch, Co-founder and
Managing Director Justin Miller called it “a very significant day”.

“There have been many major achievements and challenges along the way for Nuheara but today’s monumental milestone sees that vision become a reality, made possible by the passion, commitment and support of our great team, business partners, customers and shareholders.

“Even better that our first hearing aid product for this new market, the HP Hearing PRO, will now be released under one of the most recognised and trusted brands in the world.”

Nuheara said it’s well positioned for the new ruling with its OTC hearing aids, which will become a significant part of Nuheara’s future as it continues to bring new hearing products to market.

Shares in Nuheara were up 36.4 per cent, trading at 22.5 cents at 1:04 pm AEDT.

Related News